Tango Therapeutics, Inc. (TNGX)

24.91 +0.28 (+1.14%) USD  |  NASDAQ  |  Sep 25, 16:00
24.91 0.00 (0.00%) After-Hours: 19:59
More

Tango Therapeutics Research and Development Expense (Annual) : 129.88M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for TNGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2020. Start Trial.
Date Value
December 31, 2025 129.88M
December 31, 2024 143.92M
December 31, 2023 115.20M
Date Value
December 31, 2022 105.91M
December 31, 2021 77.64M
December 31, 2020 49.99M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Revolution Medicines, Inc. 978.68M
Beam Therapeutics, Inc. 409.62M
Erasca, Inc. 92.85M
NovelStem International Corp. --
Brainstorm Cell Therapeutics, Inc. 3.976M